Aldevron Breakthrough Blog: Vaccines

Protein Expression for Vaccine Development

Overcoming challenges in process design

Recombinant proteins are an essential component of many vaccines. However, producing these crucial proteins can be challenging. From selecting the appropriate expression system to optimizing fermentation and purification processes, there are many factors to consider when designing a process to make high-quality proteins that can be used for vaccine development.

Read More

Perspectives: Where do we go from here?

Wide-ranging potential for mRNA vaccines

Overnight success is often the result of years of effort and setbacks, which could be the life story of an mRNA pioneer, Dr. Katalin Karikó, now with the Perelman School of Medicine at the University of Pennsylvania. Karikó spent decades focusing her research on how mRNA could be used for therapies, which ultimately helped lead to the development of COVID-19 vaccines.

Read More

Structured DNA Repeats

A plasmid replication challenge

For decades, the cell and gene therapy industry has been using the same plasmid technology in vaccination, cell and gene therapy, and as a raw material in viral vector and RNA production. In some cases, that technology isn’t a good fit for the processes where it’s being used. Now, with the growing popularity of Nanoplasmid™ vectors, that is starting to change.

Read More

A Three-Step RNA Progression

An outlook for mRNA, saRNA and Circular RNA

When mRNA vaccines began to roll out in late 2020 to fight the COVID pandemic, it was the first large-scale use of the molecule after years of research. But the success of those vaccines was only the beginning of new opportunities for the RNA field.

Read More

Lessons Learned & Looking to the Future

Thoughts from the World Vaccine Congress

Managing the H1N1 outbreak in 2009 was considered a practice run for the recent SARS-CoV2 pandemic and, over the last two years, we certainly learned a great deal in being prepared for the next virus to gain a foothold. That was the backdrop as we returned to the World Vaccine Congress in Washington, DC.

Read More

The Benefits of Streamlining and Standardizing Plasmid DNA for Cell and Gene Therapies

Manufacturing standardization for cell and gene therapies (C&GT) has received increased focus in the last several years, spurred by the rapid exponential growth witnessed in this field. The resulting need for improved access to high-quality raw materials, including plasmid DNA, has made standardization integral to streamlining the development process for this biologic product category. 
Read More

The Pivotal Role of Plasmid DNA

Plasmid DNA has historically been key to the development of biologic drug manufacturing. Today, it plays a critical role in the production of next-generation cell and gene therapies and vaccines. With our nearly 23 years of plasmid DNA manufacturing expertise, Aldevron has helped facilitate the advance of these important therapeutics. We continue to invest in additional capacity and novel capabilities to support biopharma manufacturers into the future.
Read More